Peptide
Cagrilintide
Cagrilintide is used or studied for appetite suppression and related fat loss and metabolic health goals. Potential benefits and safety depend on indication, formulation, dose, and medical supervision.
In depth
How it works
Cagrilintide is a long-acting amylin analog, a different hormone pathway than GLP-1 drugs. Amylin is co-released with insulin from pancreatic beta cells and signals satiety through amylin receptors in the brainstem and hypothalamus. Cagrilintide is engineered with fatty-acid modifications similar to semaglutide's, giving it a long enough half-life for once-weekly dosing.
What the research shows
Because amylin and GLP-1 pathways are distinct but complementary, cagrilintide is primarily being developed in combination with semaglutide (as CagriSema) rather than as a standalone therapy. Combination trials (REDEFINE 1) reported average weight loss around 22.7% at 68 weeks, compared to about 16% for semaglutide alone in the same trial.
Cagrilintide (standalone or as CagriSema) is not yet FDA approved.
Detail
Overview
Cagrilintide is used or studied for appetite suppression and related fat loss and metabolic health goals. Potential benefits and safety depend on indication, formulation, dose, and medical supervision.
Benefits, side effects, and protocols
Benefits list
- Appetite suppression
Side effects
- Nausea
Vendor protocol
- None listed
Clinical protocol
- None listed
Evidence
- Low
- Phase III obesity drug
Regulatory
- Not Fda Approved
Research
Mechanisms
Evidence notes
- Low
- Phase III obesity drug
Administration
Research links
Contraindications
- None listed
Components
- None listed
Regulatory data
- Not Fda Approved
Aliases
- None listed
Used in these stacks
Related compounds
Terminology on this page
Concepts from the glossary that come up around Cagrilintide.
Frequently asked questions
What is cagrilintide used for?
Cagrilintide is an amylin-receptor agonist being developed for weight management, primarily in combination with semaglutide under the name CagriSema, where the two complementary pathways have shown greater weight loss than semaglutide alone in trials.
Is cagrilintide FDA approved?
Not on its own. The combination product CagriSema is under regulatory review but not yet approved.
Educational reference only. Pepperz does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing recommendations. Sourcing Cagrilintide? Check your source before you use anything.